FY2025 EPS Estimates for Surmodics Reduced by Zacks Research

Surmodics, Inc. (NASDAQ:SRDX) – Zacks Research decreased their FY2025 earnings per share estimates for Surmodics in a report released on Tuesday, July 1st. Zacks Research analyst D. Dey now anticipates that the company will post earnings per share of ($0.56) for the year, down from their prior estimate of ($0.54). The consensus estimate for Surmodics’ current full-year earnings is $0.20 per share. Zacks Research also issued estimates for Surmodics’ Q4 2025 earnings at ($0.18) EPS, Q1 2026 earnings at ($0.18) EPS, Q4 2026 earnings at $0.07 EPS and FY2026 earnings at ($0.09) EPS.

Surmodics (NASDAQ:SRDX) last released its quarterly earnings results on Wednesday, April 30th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.07). The company had revenue of $28.09 million for the quarter, compared to analyst estimates of $32.23 million. Surmodics had a negative return on equity of 7.10% and a negative net margin of 16.34%.

Other equities research analysts have also issued reports about the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Surmodics in a report on Wednesday, April 30th. Lake Street Capital raised shares of Surmodics from a “hold” rating to a “buy” rating and set a $43.00 price objective for the company in a research report on Friday, March 7th.

Surmodics Trading Up 3.4%

SRDX opened at $29.99 on Thursday. The firm’s 50 day moving average is $28.88 and its 200-day moving average is $31.88. Surmodics has a 52-week low of $26.00 and a 52-week high of $42.44. The company has a quick ratio of 3.99, a current ratio of 5.14 and a debt-to-equity ratio of 0.27. The firm has a market capitalization of $428.79 million, a P/E ratio of -21.57 and a beta of 1.31.

Institutional Trading of Surmodics

A number of hedge funds have recently made changes to their positions in SRDX. Rhumbline Advisers raised its position in shares of Surmodics by 4.4% during the 4th quarter. Rhumbline Advisers now owns 20,250 shares of the company’s stock valued at $802,000 after acquiring an additional 861 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of Surmodics by 17.5% during the fourth quarter. Principal Financial Group Inc. now owns 36,061 shares of the company’s stock worth $1,428,000 after purchasing an additional 5,365 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Surmodics by 1.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 117,904 shares of the company’s stock worth $4,669,000 after buying an additional 1,593 shares during the last quarter. Skandinaviska Enskilda Banken AB publ boosted its holdings in shares of Surmodics by 14.5% in the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 57,627 shares of the company’s stock valued at $2,284,000 after buying an additional 7,279 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its holdings in shares of Surmodics by 165.3% in the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 30,000 shares of the company’s stock valued at $1,188,000 after buying an additional 18,692 shares during the period. Institutional investors and hedge funds own 96.63% of the company’s stock.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).